Global Variability in HTA Decisions Poses Challenges for Innovative Biopharmaceutical Research and Development

In recent years, technology appraisals and reimbursement recommendations from established health technology assessment (HTA) organizations around the globe are taking on an increasingly prominent role in cost-containment and seem to have become more restrictive in nature. In order for important new health technologies to reach patients, innovative research companies must achieve market access not only through stringent regulatory processes, but also by gaining reimbursement approval from many countries around the world.

NICE Limits Reimbursement for Oncology Products beyond EMA Product Labeling

In recent years, technology appraisals and reimbursement recommendations from established health technology assessment (HTA) organizations around the globe are taking on an increasingly prominent role in cost-containment and seem to have become more restrictive in nature. As HTAs have become a prominent element of health care decision-making in many countries, attention is turning to whether they assess outcomes and measures that are most meaningful to patients and their physicians.

Barriers Created by UK NICE

The approach used in the United Kingdom, and other European countries, to make coverage or reimbursement decisions for new tests and treatments based on a centralized value assessment is sometimes pointed to as a model for the U.S. However, new analysis illustrates how the use of a cost‐effectiveness standard by the UK’s National Institute for Health Care Excellence (NICE) as the basis for coverage decisions often creates barriers to patient access to beneficial new treatment options.

Prescription Management is Critical for Diabetes Patients

07.10.14 | By

Patients, especially those suffering from chronic conditions, deserve access to the medicines they need to live longer, healthier lives. The Affordable Care Act’s health insurance exchanges and the Essential Health Benefits they’re meant to provide were supposed to ensure patients have access to the treatments they need. But for many, high out-of-pocket costs create a sometimes insurmountable barrier to access.

Diabetes By the Numbers Graphic

Negotiators Push Ahead on TPP in Canada

07.08.14 | By

Today, the countries participating in the Trans-Pacific Partnership (TPP) agreement begin yet another round of negotiations in Ottawa, Canada. The TPP is a trade deal currently being negotiated between the U.S. and 11 countries in the Pacific Rim region, including Canada and Japan. The agreement is predicted to increase U.S. exports by $125 billion and help transform how business is conducted in the global economy.

STEM Saves Lives Remarks

Access to Asthma Medicine and the Risk of Going Without

07.08.14 | By

Patients, especially those suffering from chronic conditions, deserve access to the medicines they need to live longer, healthier lives. The Affordable Care Act’s health insurance exchanges and the Essential Health Benefits they’re meant to provide were supposed to ensure patients have access to the treatments they need. But for many, high out-of-pocket costs create a sometimes insurmountable barrier to access.

Prevention Saves

07.03.14 | By

Vaccines are a critical medical advancement that has saved countless lives. Through the hard work and dedication of researchers around the world, vaccines have eradicated devastating diseases including smallpox, polio, rubella and the measles, and at least 90 percent eradicated 10 additional infectious diseases. Today, vaccines prevent hepatitis A and B, pneumonia and some cancers and have contributed to the global lifespan increase of six years between 1990 and 2012.

Week in Review: Celebrating Patient Health

07.03.14 | By

Before we leave to celebrate the holiday weekend, we wanted to talk about the latest happenings in the biopharmaceutical industry and the importance of celebrating patients.

Pages

Subscribe to RSS - Opinion